Oncoscience

Pretreatment prostate specific antigen doubling time as prognostic factor in prostate cancer patients

Gennady M. Zharinov1, Oleg A. Bogomolov1, Natalia N. Neklasova1, Vladimir N. Anisimov2

1Department of Radiotherapy, The Russian Research Center of Radiology and Surgical Technologies, St. Petersburg, Russia

2Department of Carcinogenesis and Oncogerontology, N.N. Petrov Research Institute of Oncology, St. Petersburg, Russia

Correspondence to:

Vladimir N. Anisimov, email: aging@mail.ru

Keywords: prostate-specific antigen, prostate cancer, PSADT, PSA doubling time, education rate

Received: October 27, 2016     Accepted: November 04, 2016     Published: February 24, 2017     

ABSTRACT

Despite the prostate-specific antigen (PSA) serum level commonly uses as tumor marker in diagnosis of prostate cancer, it seems that PSA doubling time (PSADT) could be more useful indicator of tumor behavior and of prognosis for patients. The results of hormone and radiation therapy were evaluated for 912 prostate cancer having at least 2 PSA tests before the treatment was started. Clustering procedure (selection of homogenous group) was performed by using PSADT as the classification marker. The rate of PSADT was estimated for different dissemination rate, age, Gleasons’s score and education level. PSADT index inversely correlated with the rate of prostate cancer dissemination, Gleason’s score and the level of education were directly correlated with the age of patients. Survival time was longer and PSADT index was higher in “slow” tumor growing subgroups in local, local-advanced and metastatic prostate cancer patients than these in “fast” subgroups. The study confirmed the prognostic value of pretreatment PSADT in prostate cancer patients independently of cancer progression. No significant relationship exists between the authors and the companies/organizations whose products or services may be referenced in this article.


PII: 337